The European Biopharma-Exchange is about to end on go-dove.com. There are several lots from France and Switzerland and from lot 1000 available. For direct access to the catalogue : http://www.go-dove.com/fr/events-BIOP0902%2CBIOP0924%2CBIOP0925/lots...
Read more
Blog
Protalix Phase I/II for Fabry Disease
Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...
Read more
Mazor Robotics Reaches India
Mazor Robotics Ltd. (TASE: MZOR) has installed a robotic system for spine surgeries in Apollo Hospitals Chennai, the flagship hospital of the Apollo Group, one of the largest healthcare groups in Asia with over 8500 beds across 50 hospitals. Mazor Robotics’ flagship product, Renaissance™, is a surgical robotic system that...
Read more
RedHill To List on NASDAQ / Successful MS Studies
RedHill Biopharma has filed with the U.S. Securities and Exchange Commission a non-public first draft registration statement to enable the listing of Company’s shares through a Level II ADR (American Depository Receipt) facility. Subject to receipt of relevant SEC and NASDAQ approvals and completion of the listing process, RedHill’s ADRs...
Read more
BioLineRX Hepatitis C Trial Succeeds
BioLineRx it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013. BL-8020 is an orally available HCV treatment with...
Read more